Analyst Insight: Justifying A Price Target Following Poor SPAC Reception
In a discussion with Medtech Insight, analysts at Ladenburg Thalmann argued the case for their LumiraDX $14.75 price target.
You may also be interested in...
Diagnostics such as c-reactive protein tests are more sensitive than ever before, but manufacturers are still struggling to place them in primary care and community settings where they can make huge differences.
Investors have been wary of LuminaraDX since its placement on NASDAQ, driving the share price down.
The $1.1bn acquisition of drug-eluting balloon developer MedAlliance will help Cordis return to its roots as an innovative leader in interventional cardiology.